Table 2 Effect of dezamizumab on measures of cardiac amyloid.

DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; N/A, not applicable.

Subject numberAmyloid typeDose of dezamizumab (mg)*LV mass
Predose (g)
LV mass
Day 42 (g)
Cardiac DPD scan
018AL600258246N/A
1200248249
1200254243
020AL600213211N/A
021AL600264244N/A
1200251228
1200225220
023ATTR1200248255Perugini grade 2
cardiac uptake. No
change
024ATTR1000255260Perugini grade 2
cardiac uptake. No
change
025ATTR600196205Perugini grade 2
cardiac uptake. No
change

*Dezamizumab was administered in two equal infusions, each lasting about 6 hours, on days 1 and 2.